Kevin Bray

The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer.

K. Brown, Lingbao Ai, B. Demircan, 2008, Carcinogenesis.

Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning

Jason T Giurleo, M. Retter, R. Tavaré, 2021, Scientific Reports.

A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells.

M. Retter, G. Thurston, Prachi Sharma, 2021, Blood advances.

Allogeneic CD20‐targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B‐cell lymphoma models

Z. An, S. Abbot, Swapna Panuganti, 2022, Clinical & translational immunology.

The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer.

K. Brown, Lingbao Ai, B. Demircan, 2008, Carcinogenesis.